Короткий опис(реферат):
Hladkykh FV. Therapeutic potential of conditioned media from mesenchymal stem cells in regulating NO production in kidney disease. Materials of the 4th International scientific-rractical conference "Science in motion: classic and modern tools and methods in scientific investigations"; February 21, 2025; Vinnytsia-Vienna (Austria): International Centre Corporative Management & European Scientific Platform; 2025, р. 1190–2. DOI: https://doi.org/10.5281/zenodo.14913939
Для цитування:
Nitric oxide (NO) is a vital signaling molecule that plays an essential role in numerous physiological processes, including the regulation of blood pressure, immune response, and neurotransmission. It is widely recognized for its vasodilatory properties, which help in the relaxation of blood vessels, and it acts in concert with other gaseous molecules like hydrogen sulfide (H2S) and carbon monoxide (CO). NO is synthesized from the amino acid L-arginine by a group of enzymes known as nitric oxide synthases (NOS). These enzymes catalyze the conversion of L-arginine into L-citrulline and NO, with three major isoforms identified: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). These isoforms are expressed in various tissues, including the kidneys, where they contribute to maintaining renal function by regulating blood flow, glomerular filtration, and interstitial pressure. NO production in the kidney is crucial for maintaining the balance of vasodilation and vasoconstriction, and it is produced by different kidney cell types, such as endothelial cells, mesangial cells, and podocytes. Podocyte injury is a hallmark of membranous nephropathy (MN), a condition characterized by the deposition of immune complexes beneath the glomerular visceral epithelial cells. The immune-mediated damage to podocytes leads to proteinuria and progressive kidney dysfunction. In recent years, there has been growing interest in the potential therapeutic use of cryopreserved biological agents (CfBA), such as conditioned media from mesenchymal stem cells (MSC-CM), as a potential treatment for autoimmune kidney diseases like MN. These agents are believed to have regenerative properties and may help modulate various biological pathways, including those involving NO.
